Dapagliflozin cost-effectiveness analysis in heart failure patients in Egypt

Magdy Abdelhamida Cardiology Department, Faculty of Medicine, Cairo University, Giza, Egypt

Gihan Hamdy Elsisib HTA Office, LLC, Cairo, Egypt;c Faculty of Economics and Political Sciences, American University in Cairo, Cairo, EgyptCorrespondence[email protected]

https://orcid.org/0000-0002-2917-9388

Ahmed Seyamd Universal Health Insurance Authority, Cairo, Egypt

Ahmed Shafiee Cardiology Department, Faculty of Medicine, Zagazig University, Giza, Egypt

Mary Kirollosf Health Technology Assessment Department, Egyptian Authority for Unified Procurement, Medical Supply and Management of Medical Technology (UPA), Cairo, Egypt

Sandy Emadg Pharmacoeconomic Unit, Egyptian Drug Authority, Giza, Egypt

Shady Mansyh Health Insurance Organization, Cairo, Egypt

Mohamed Sobhyi Cardiology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt

show all

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Articles from other publishers (6)

Eui-Soon Kim, Sun-Kyeong Park, Daniel Sung-ho Cho, Jong-Chan Youn, Hye Sun Lee, Hae-Young Lee, Hyun-Jai Cho, Jin-Oh Choi, Eun-Seok Jeon, Sang Eun Lee, Min-Seok Kim, Jae-Joong Kim, Kyung-Kuk Hwang, Myeong-Chan Cho, Shung Chull Chae, Seok-Min Kang, Jin Joo Park, Dong-Ju Choi, Byung-Su Yoo, Jae Yeong Cho, Kye Hun Kim, Byung-Hee Oh, Barry Greenberg & Sang Hong Baek. (2024) Eligibility and Cost-Utility Analysis of Dapagliflozin in Patients with Heart Failure Across the Whole Spectrum of Ejection Fraction in South Korea. American Journal of Cardiovascular Drugs.
Crossref

Yi Jing Tan, Siew Chin Ong & Ying Min Kan. (2023) Is Using Sodium-Glucose Cotransporter-2 Inhibitors to Treat Adults with Chronic Heart Failure Cost-Effective? A Systematic Review of Cost-Effectiveness Studies. Applied Health Economics and Health Policy 21:6, pages 857-875.
Crossref

He Lu, Pingping Shang & Dexing Zhou. (2023) SGLT2 inhibitors for patients with heart failure with preserved ejection fraction in China: a cost-effectiveness study. Frontiers in Pharmacology 14.
Crossref

Yi Tang & Haiqiang Sang. (2023) Cost‐utility analysis of add‐on dapagliflozin in heart failure with preserved or mildly reduced ejection fraction. ESC Heart Failure 10:4, pages 2524-2533.
Crossref

Kyungae Nam, Daniel Sung-Ho Cho, Hyunji Kim, Byungjin Kwon, Yebin Yoon, Chanhyun Park, Eui-Soon Kim, Jong-Chan Youn & Sun-Kyeong Park. (2023) Systematic Review of the Economic Evaluation of Sodium–Glucose Cotransporter-2 Inhibitors Used as Treatment in Patients with Heart Failure. Clinical Drug Investigation 43:7, pages 463-474.
Crossref

Aziz Rezapour, Mahsa Tashakori-Miyanroudi, Majid Haghjoo, Mohammad Barzegar, Parvin Tatarpour, Aghdas Souresrafil, Hassan Abolghasem Gorji, Negar Yousefzadeh & Mohammadreza Sheikhy-Chaman. (2023) Cost Effectiveness of Adding Dapagliflozin to Standard Care in Heart Failure Patients with Reduced Ejection Fraction: A Systematic Review. American Journal of Cardiovascular Drugs 23:2, pages 127-144.
Crossref

Dapagliflozin cost-effectiveness analysis in heart failure patients in Egypt

Articles from other publishers (6)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Dapagliflozin cost-effectiveness analysis in heart failure patients in Egypt

Citations (6)

Articles from other publishers (6)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date